AR039219A1 - Compuestos imidazo-sustituidos - Google Patents
Compuestos imidazo-sustituidosInfo
- Publication number
- AR039219A1 AR039219A1 ARP030101141A ARP030101141A AR039219A1 AR 039219 A1 AR039219 A1 AR 039219A1 AR P030101141 A ARP030101141 A AR P030101141A AR P030101141 A ARP030101141 A AR P030101141A AR 039219 A1 AR039219 A1 AR 039219A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- bond
- alkyl
- atoms
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos correspondientes a la fórmula (1), así como también formulaciones farmacéuticas, métodos de preparación y usos de los mismos para el tratamiento de enfermedades mediadas por p38. Reivindicación1: Un compuesto representado por la fórmula 1 caracterizado porque Z es N o CH, Z1 es seleccionado entre N y CH cuando el enlace entre los átomos C5 y Z1 es un enlace simple, y Z1 es C cuando el enlace entre C5 y Z1 es un enlace doble; R1 es H o alquilo; R2 es alquilo, hidroxialquilo, aralquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heteroalquilo, heterociclilo opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; A está ausente o es -O-, -S(O)n-, -CHR´-, -C(=O)- o -NR3- en donde n es 0,1, o 2, R´ es H o alquilo y R3 es H, alquilo, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o cicloalquilo opcionalmente sustituido; el enlace entre los átomos C5 y Z1 es un enlace simple o doble; el enlace entre los átomos C8 y C9 es un enlace simple o doble; e Y es un alquilo, heteroalquilo, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; o isómeros, sales farmacéuticamente aceptables, ésteres o prodrogas del mismo. Reivindicación 29: El uso de acuerdo con la reivindicación 28, caracterizado porque el trastorno mediado por p38 es seleccionado entre el grupo que consiste en artritis, enfermedad de Crohn, enfermedad de Alzheimer, síndrome del colon irritable, síndrome de la insuficiencia respiratoria del adulto y enfermedad pulmonar obstructiva crónica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36992902P | 2002-04-03 | 2002-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039219A1 true AR039219A1 (es) | 2005-02-09 |
Family
ID=28675587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101141A AR039219A1 (es) | 2002-04-03 | 2003-04-02 | Compuestos imidazo-sustituidos |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US6949560B2 (es) |
| EP (1) | EP1492790A1 (es) |
| JP (1) | JP2006503802A (es) |
| KR (1) | KR100656205B1 (es) |
| CN (1) | CN1293078C (es) |
| AR (1) | AR039219A1 (es) |
| AU (1) | AU2003215675B2 (es) |
| BR (1) | BR0308937A (es) |
| CA (1) | CA2479644A1 (es) |
| MX (1) | MXPA04009585A (es) |
| PL (1) | PL374544A1 (es) |
| RU (1) | RU2310657C2 (es) |
| WO (1) | WO2003082871A1 (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050070554A1 (en) * | 2003-08-27 | 2005-03-31 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| FR2873118B1 (fr) * | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| WO2008114119A2 (en) * | 2007-03-20 | 2008-09-25 | Cadila Pharmaceuticals Limited | P38 inhibitors |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| KR20140094559A (ko) * | 2011-10-21 | 2014-07-30 | 글락소스미스클라인 엘엘씨 | 선천 면역 반응을 증강시키기 위한 화합물 및 방법 |
| SG11201408238WA (en) | 2012-06-13 | 2015-01-29 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| CN105481858B (zh) * | 2014-10-11 | 2019-05-17 | 上海医药集团股份有限公司 | 一种含氮稠杂环化合物、其制备方法、组合物及应用 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2017075274A1 (en) | 2015-10-27 | 2017-05-04 | Children's Hospital Medical Center | Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| KR20180002053A (ko) * | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
| WO2018004258A1 (ko) * | 2016-06-28 | 2018-01-04 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
| CN109906227B (zh) * | 2016-11-16 | 2022-03-11 | 上海瑛派药业有限公司 | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 |
| RU2745035C1 (ru) * | 2017-02-27 | 2021-03-18 | Бетта Фармасьютикалз Ко., Лтд. | Ингибитор fgfr и его применение |
| WO2018214846A1 (zh) * | 2017-05-23 | 2018-11-29 | 成都优赛丽医药科技有限公司 | 咪唑并[1',2'：1,6]吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| KR102421137B1 (ko) * | 2017-10-30 | 2022-07-13 | 상하이 린진 바이오파마 씨오., 엘티디. | 아미노치환 질소함유 축합고리 화합물 및 그의 제조방법과 용도 |
| WO2019085894A1 (zh) * | 2017-10-30 | 2019-05-09 | 如东凌达生物医药科技有限公司 | 一类含氮稠环化合物及其制备方法和用途 |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| WO2019213506A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
| WO2020038458A1 (zh) * | 2018-08-23 | 2020-02-27 | 如东凌达生物医药科技有限公司 | 一类稠环三氮唑类化合物、制备方法和用途 |
| TW202024084A (zh) * | 2018-08-27 | 2020-07-01 | 大陸商貝達藥業股份有限公司 | 新型氮雜三環類化合物的鹽型、晶型及其用途 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| KR20210131369A (ko) * | 2019-03-08 | 2021-11-02 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | Fgfr4 키나아제 억제제 및 이의 제조 방법과 용도 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220064369A (ko) | 2019-08-14 | 2022-05-18 | 인사이트 코포레이션 | Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물 |
| WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2022032071A1 (en) * | 2020-08-07 | 2022-02-10 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522947A (en) | 1982-03-29 | 1985-06-11 | Usv Pharmaceutical Corporation | Certain 1,3-oxazolo[4,5H]quinolines useful as anti-allergy agents |
| US4656281A (en) | 1983-03-18 | 1987-04-07 | Usv Pharmaceutical Corp. | Imidazo quinoline compounds useful as anti-allergy agents |
| DE3502689A1 (de) | 1985-01-26 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Elektrophotographisches aufzeichnungsmaterial |
| US4831040A (en) | 1988-02-01 | 1989-05-16 | Rorer Pharmaceutical Corporation | Method of prevention and treatment of peptic ulcers |
| GB9123916D0 (en) | 1991-11-11 | 1992-01-02 | Wellcome Found | Heterocyclic compounds |
| JPH11292878A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | イミダゾナフチリジン誘導体 |
| ES2280247T3 (es) * | 1999-10-21 | 2007-09-16 | F. Hoffmann-La Roche Ag | Heterociclos de nitrogeno biciclicos heteroalquilamino sustituidos como inhibidores de proteinas de quinasa p38. |
| WO2002018380A1 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| DK1361880T3 (da) | 2001-02-12 | 2006-01-23 | Hoffmann La Roche | 6-substituerede pyrido-pyrimidiner |
-
2003
- 2003-03-27 MX MXPA04009585A patent/MXPA04009585A/es active IP Right Grant
- 2003-03-27 EP EP03745276A patent/EP1492790A1/en not_active Withdrawn
- 2003-03-27 CN CNB038075369A patent/CN1293078C/zh not_active Expired - Fee Related
- 2003-03-27 RU RU2004132204/04A patent/RU2310657C2/ru active
- 2003-03-27 AU AU2003215675A patent/AU2003215675B2/en not_active Ceased
- 2003-03-27 CA CA002479644A patent/CA2479644A1/en not_active Abandoned
- 2003-03-27 JP JP2003580336A patent/JP2006503802A/ja active Pending
- 2003-03-27 KR KR1020047015609A patent/KR100656205B1/ko not_active IP Right Cessation
- 2003-03-27 PL PL03374544A patent/PL374544A1/xx not_active Application Discontinuation
- 2003-03-27 BR BR0308937-1A patent/BR0308937A/pt not_active IP Right Cessation
- 2003-03-27 WO PCT/EP2003/003178 patent/WO2003082871A1/en active IP Right Grant
- 2003-04-02 AR ARP030101141A patent/AR039219A1/es unknown
- 2003-04-03 US US10/406,364 patent/US6949560B2/en not_active Expired - Fee Related
-
2005
- 2005-05-04 US US11/122,137 patent/US7081462B2/en not_active Expired - Fee Related
-
2006
- 2006-07-13 US US11/486,348 patent/US7285561B2/en not_active Expired - Fee Related
- 2006-07-13 US US11/486,193 patent/US7285559B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7081462B2 (en) | 2006-07-25 |
| US20030232847A1 (en) | 2003-12-18 |
| AU2003215675A1 (en) | 2003-10-13 |
| US6949560B2 (en) | 2005-09-27 |
| WO2003082871A1 (en) | 2003-10-09 |
| RU2310657C2 (ru) | 2007-11-20 |
| US20060252784A1 (en) | 2006-11-09 |
| EP1492790A1 (en) | 2005-01-05 |
| US20060252783A1 (en) | 2006-11-09 |
| BR0308937A (pt) | 2005-01-04 |
| MXPA04009585A (es) | 2005-01-11 |
| CN1646529A (zh) | 2005-07-27 |
| JP2006503802A (ja) | 2006-02-02 |
| US7285559B2 (en) | 2007-10-23 |
| AU2003215675B2 (en) | 2007-07-12 |
| US7285561B2 (en) | 2007-10-23 |
| CA2479644A1 (en) | 2003-10-09 |
| US20050197352A1 (en) | 2005-09-08 |
| CN1293078C (zh) | 2007-01-03 |
| KR20040099384A (ko) | 2004-11-26 |
| RU2004132204A (ru) | 2005-11-20 |
| KR100656205B1 (ko) | 2006-12-12 |
| PL374544A1 (en) | 2005-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039219A1 (es) | Compuestos imidazo-sustituidos | |
| MX2022005399A (es) | Compuestos. | |
| AR047976A1 (es) | Compuestos inmunosupresores y composiciones | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| UY31084A1 (es) | Compuestos de azaindol para la inhibicion de b-secretasa | |
| UY31083A1 (es) | Derivados de sulfoximinas para la inhibicion de b-secretasa | |
| UY29927A1 (es) | Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| UY30408A1 (es) | Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| BRPI0518651A2 (pt) | composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| UY28578A1 (es) | Derivados de amida | |
| AR058901A1 (es) | Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| BR0112475A (pt) | N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina | |
| GT200400174A (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5 ht4 | |
| AR053344A1 (es) | Antagonistas del cgrp,procedimiento para su preparacion,composiciones farmaceuticas que los contienen y usos para el tratamiento de la migrana y otras enfermedades | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| NO20081128L (no) | 4-fenyl-6-substituerte-pyrimidin-2-karbonitrilderivater | |
| AR064657A1 (es) | 8- alquinilxantinas y derivados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |